key: cord-0818768-tk3f79g7
authors: Rauch, Susanne; Roth, Nicole; Schwendt, Kim; Fotin-Mleczek, Mariola; Mueller, Stefan O.; Petsch, Benjamin
title: mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
date: 2020-10-23
journal: bioRxiv
DOI: 10.1101/2020.10.23.351775
sha: 6f87a96ec83b37bb2d02aaf50890a9b910153e0f
doc_id: 818768
cord_uid: tk3f79g7

The devastating SARS-CoV-2 pandemic demands rapid vaccine development and large scale production to meet worldwide needs. mRNA vaccines have emerged as one of the most promising technologies to address this unprecedented challenge. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle (LNP) encapsulated non-modified mRNA vaccine that encodes the full length, pre-fusion stabilised SARS-CoV-2 Spike (S) protein. S translated from CVnCoV is cleaved, post-translationally modified, and presented on the cell surface, highlighting the ability of mRNA vaccines to mimic antigen presentation during viral infection. Immunisation with CVnCoV induced strong humoral responses with high titres of virus neutralizing antibodies in mice and hamsters and robust CD4+ and CD8+ T cell responses in mice. Most importantly, vaccination with CVnCoV fully protected hamster lungs from challenge with wild type SARS-CoV-2. To gain insights in the risk of vaccine-enhanced disease, hamsters vaccinated with a suboptimal dose of CVnCoV leading to breakthrough viral replication were analysed for signs of vaccine-enhanced disease. No evidence of increased viral replication or exacerbated inflammation and damage to viral target organs was detectable, giving strong evidence for a favourable safety profile of CVnCoV. Overall, data presented here provide evidence that CVnCoV represents a potent and safe vaccine candidate against SARS-CoV-2.

The global COVID-19 pandemic has highlighted the need for novel technologies that allow rapid development and production of human vaccines against newly emerging infectious pathogens.

Following pioneering work using mRNA formulated with protamine to target tumours (Hoerr et al., 2000) , (Fotin-Mleczek et al., 2012) , (Fotin-Mleczek et al., 2011) , (Kubler et al., 2015) , CureVac has established that mRNA elicits immune responses against target antigens as a prophylactic vaccine (Stitz et al., 2017) , (Lutz et al., 2017) , (Schnee et al., 2016) , (Petsch et al., 2012) , (Alberer et al., 2017) . CureVac's proprietary mRNA technology is designed to rapidly identify, produce, and test stable and immunogenic mRNA molecules (Rauch et al., 2018) . Following preclinical proof of concept with rabies glycoprotein RABV-G mRNA, formulated with protamine (Petsch et al., 2012) , (Schnee et al., 2016) , a first-in-human study showed that immune responses are elicited in adult volunteers, although protective titres could only be induced when specialised injection devices were used (Alberer et al., 2017) . Further research has demonstrated that RABV-G mRNA encapsulated in lipid nanoparticles (LNP) overcomes these deficiencies and significantly improves vaccine efficacy in animal models (Lutz et al., 2017) , and in human volunteers [CureVac, data in preparation for publication]. mRNA technology is now the basis for several SARS-CoV-2 vaccine candidates (e.g. ; , (Anderson et al., 2020) , (Kalnin et al., 2020) . The main antigenic target of SARS-CoV-2 is the glycosylated spike protein (S) which interacts with human angiotensin-converting enzyme 2 (ACE2). Consistent with the mode of action of SARS-CoV, which first emerged in 2002 -2003 (Li et al., 2003 , ACE2 binding allows cellular entry of the virus (Hoffmann et al., 2020b; Letko et al., 2020) . S is a trimeric glycoprotein complex located on the viral surface, and is a critical target for viral neutralizing antibodies . Each monomer consists of two domains, S1 and S2, that act separately to mediate viral binding and fusion to the host cell membrane, respectively. The S1 domain interacts with cell-surface receptors through a receptor binding domain (RBD) . Monoclonal antibodies (mAb) against the RBD have neutralizing capacity (Chi et al., 2020) .

Fusion with the membrane through S1 leads to a conformational change in the spike protein, proteolytic cleavage of the S1 and S2 domains, and ultimately, viral uptake and replication , (Shang et al., 2020) .

CureVac has applied its mRNA technology to the rapid development of CVnCoV, a SARS-CoV-2 vaccine designed for maximal protein expression and balanced immune activation. CVnCoV is comprised of lipid nanoparticle (LNP)-formulated, non-chemically modified, sequence engineered mRNA encoding full length S protein with two proline mutations (S-2P). These mutations stabilize protein conformation as previously reported for MERS-CoV (Pallesen et al., 2017) and SARS-CoV (Kirchdoerfer et al., 2018) . Here we describe the immunogenicity and protective efficacy of CVnCoV in preclinical studies. This work has supported the start of CVnCoV clinical development, currently in phase 2 clinical studies.

CVnCoV encodes for full-length SARS-CoV-2 S protein with intact S1/S2 cleavage site and transmembrane domain, as well as K986P and V987P mutations (Pallesen et al., 2017) , (Kirchdoerfer et al., 2018 ) (S-2P) ( Figure 1A ). Non-encapsulated SARS-CoV-2 S-2P mRNA translated in a cell free in vitro system yielded a 140 kDa protein, representing uncleaved full length S-2P ( Figure 1B ). Efficient cleavage of the S-2P protein in cell culture was demonstrated by Western blot analysis of mRNA transfected cells, using an antibody directed against the S2 portion of the protein (Hoffmann et al., 2020a) , (Hoffmann et al., 2020b) . This analysis showed the generation of two main bands of approx. 90 kDa and 180 kDa, likely reflecting glycosylated forms of unprocessed S protein (S0) and the cleaved S2 subunit ( Figure 1C ). In agreement with an intact signal peptide and transmembrane domain, further flow cytometric analyses proved that a large proportion of mRNA encoded SARS-CoV-2 S localised to the surface of mRNA transfected cells.

To characterise mRNA-induced innate and adaptive immune responses, Balb/c mice were immunised with 2 µg of LNP-formulated mRNA encoding SARS-CoV-2 S-2P (CVnCoV). Innate responses were assessed in sera of CVnCoV vaccinated mice 14 hours post injection, the time point when mRNAinduced pro-inflammatory cytokines and chemokines peak (Lutz et al., 2017) . These analyses demonstrated the induction of a balanced immune response upon CVnCoV injection that exhibited no bias towards IFN or IL4, IL-5 and IL-13, indicative of a TH1 and TH2 response, respectively. Low levels of pro-inflammatory cytokines IL-6, IFN were detectable in serum, while TNF and IL1 remained undetectable ( Figure 2A ).

To determine immunization schedule impact, two injections of CVnCoV were given 4, 3, 2 or 1 week apart, i.e. on d0/d28, d7/d28, d14/d28 or d21/d28. Spike ectodomain (SECD)-binding antibodies, found to correlate with the induction of virus neutralizing antibodies in COVID-19 patients (Salazar et al., 2020) , developed rapidly upon a single injection with CVnCoV. Seven days after a single vaccination, robust IgG1 and IgG2a titres were present and increased over time ( Figure 2B ). Median endpoint titres on day 7 were 3.1 x 10 4 and 4.7 x 10 5 , for IgG1 and IgG2a, respectively, and increased to 3.9 x 10 6 for both IgG1 and IgG2a on d28. Second injection with CVnCoV induced increase in SECD-binding IgG1 and IgG2a antibodies, while a trend towards lower immune responses induced by shorter intervals between first and second vaccination remained detectable until termination of the experiment in week 7 (d49).

As expected, Alum-adjuvanted SECD protein domain, employed as a control for TH2 biased responses, induced high titres of IgG1 but comparatively low levels of IgG2a. Induction of virus neutralizing titres (VNTs) in mouse sera was assessed in a cytopathic effect (CPE)-based assay with wild-type SARS-CoV-2. Detectable levels of VNTs started to develop 4 weeks after a single injection, while a second injection led to significant VNT increase in all groups. Analyses one and three weeks after the second vaccination showed that responses rose over time ( Figure 2C ). By termination on day 49, all sera derived from animals vaccinated on d0/28 were able to neutralise 50% of infecting virus (100 TCID50) in cell culture at a dilution of 1:5120. For comparison, two serum samples from symptomatic convalescent subjects chosen for the presence of high levels of binding antibodies provided titres of 1:320 -1:640.

Strong induction of IFN/TNF double positive T cells in CVnCoV-vaccinated mice ( Figure 2D ) was demonstrated by T cell analyses via intracellular staining (ICS) of splenocytes isolated 3 weeks after the second vaccination (d49). T cell responses benefited from longer intervals between first and second vaccination. Highest responses were detected in animals vaccinated on d0/d28 with median values of IFN + /TNF + CD4 + and CD8 + T cell of 0.34% and 10.5%, respectively. In contrast, IFN + /TNF + CD4 + or CD8 + T cells remained undetectable in the protein control group.

Mice vaccinated with CVnCoV doses of 0.25 µg, 1 µg or 4 µg elicited dependent humoral responses.

IgG1 and IgG2a antibodies induced by CVnCoV interacted with SECD, the isolated S receptor binding domain (RBD), the trimeric form of the S-protein (S trimer), and with the isolated N-terminal domain (NTD) ( Figure 3A ). CVnCoV induced comparable levels of SECD, RBD and trimeric S reactive antibodies, with the exception of the lowest 0.25µg dose, which generated lower RBD responses. Of note, antibodies directed against the NTD, an alternative target of VNTs next to the RBD (Salazar et al., 2020) , were detectable for all doses but overall remained lower than levels of SECD-, RBD-and S trimer-binding antibodies. As observed previously, VNTs started to develop 3 weeks after a single vaccination and robust levels were detectable after a second vaccination with titres of 1:2560 and 1: 5120 for the 1 µg and 4 µg dose groups, respectively. Even the lowest dose of 0.25µg induced detectable levels of VNTs of approximately 1:14 ( Figure 3B ). Further experiments demonstrated comparable relative avidity for SECD specific IgG1 and IgG2a antibodies ( Figure 3C ). CVnCoV-induced antibodies that efficiently competed with a neutralizing monoclonal antibody for binding to native SARS-CoV-2 S expressed on the cellular surface ( Figure 3D ).

Next, we sought to address the protective efficacy of CVnCoV in Syrian hamsters. This model represents mild to moderate human lung disease pathology, and is one of the recognized and accepted models to investigate human-relevant immunogenicity and pathogenesis (Munoz-Fontela et al., 2020) . Hamsters are susceptible to wild-type SARS-CoV-2 infection, resulting in high levels of virus replication and histopathological changes in viral target organs. Animals vaccinated with two CVnCoV doses of 2 µg or 10 µg in a 4-week interval developed dose-dependent SECD binding IgG antibodies after the first vaccination that increased upon the second ( Figure 4A ). Median endpoint titres of animals vaccinated with 10 µg of CVnCoV were 1.6 x 10 5 after one dose and peaked at 7.8 x 10 5 on day 42. Binding antibody titres were not assessed in animals previously infected with SARS-CoV-2. In agreement with mouse results generated in a similar assay with varied incubation time, CPE-based VNT analysis showed that two vaccinations with 10 µg of CVnCoV were able to induce robust levels of neutralising titres in hamsters. The median titres peaked at 1:134 on day 42. For comparison, control animals infected with wild-type SARS-CoV-2 on day 0 developed VNTs of 1:191. Of note, a control group that received Alumadjuvanted SECD protein developed IgG antibodies but undetectable VNT levels ( Figure 4B ).

On day 56, four weeks after the second vaccination, all animals were challenged with 10 2 TCID50/dose of wild-type SARS-CoV-2. Buffer control animal throat swabs, taken daily from day 56 to termination on day 60, showed peak replication-competent viral titres of approximately 10 3 TCID50/ml two days post challenge. These titres were nearly undetectable on d60. Animals previously infected with SARS-CoV-2 remained negative throughout the experiment. Viral levels were significantly reduced in throat swabs of both CVnCoV-vaccinated groups. Vaccination with 10 µg of CVnCoV resulted in significantly diminished and delayed viral peaks at 10 1.5 TCID50/ml three days post challenge. At least 2 out of 5 animals in this group remained negative throughout the testing period (Figure 4 C). Viral levels in nasal turbinates revealed less pronounced, but detectable dose-dependent reduction of viral replication ( Figure 4D ). Importantly, animals vaccinated with 10 µg of CVnCoV exhibited no detectable viral levels in the lungs, proving the ability of CVnCoV to protect animals from viral replication in the lower respiratory tract ( Figure 4E ).

Histopathological analyses demonstrated the occurrence of alveolar damage and inflammation of alveoli, bronchi and trachea in the buffer control group upon SARS-CoV-2 infection, proving the suitability of this model to assess virus-induced pathology. Consistent with protection from viral replication in the lungs, CVnCoV significantly reduced histopathological changes upon two vaccinations with 10 µg. Importantly, a dose of 2 µg, which led to the induction of binding antibodies with low levels of VNTs, did not induce increased histopathology scores. Therefore, we conclude that CVnCoV does not induce enhanced disease in hamsters, even under conditions where breakthrough viral replication occurs. The presented data give indication that Alum-adjuvanted protein vaccine, which induces a TH2 shifted immune response with no detectable levels of VNTs but high levels of binding antibodies, causes increased histopathology scores in hamsters ( Figure 5 ).

Here we show that CVnCoV mRNA translated into a protein, that was cleaved, post-translationally modified, and presented on the cell surface, mimicking viral protein presentation during infection. In line with previous results (Lutz et al., 2017) , CVnCoV induced innate immune responses, including IL-6 and IFNin mice, indicative of a pro-inflammatory environment for the induction of cellular and humoral immune responses. Incorporation of two prolines that prevent structural rearrangement to the postfusion state of coronaviurs S proteins (Kirchdoerfer et al., 2018) , (Pallesen et al., 2017) in the CVnCoV design was aimed to increase S-induced immune responses as observed in the context of MERS (Pallesen et al., 2017) . Indeed, vaccination with CVnCoV induced robust humoral responses featuring high levels of virus neutralizing titers in mice and hamsters that were dose-and vaccination scheduledependent. Antibody responses in mice developed rapidly upon injection and were reactive with both S domains targeted by human VNTs, i.e. the RBD domain as the primary target of neutralizing antibodies, (Walls et al., 2020) , (Wrapp et al., 2020) as well as the NTD . CPE-based detection of virus neutralizing antibody responses in mice and hamsters revealed that CVnCoV induced high levels of VNTs upon two injections. In hamsters, VNTs were comparable to titres induced upon natural infection with wild type SARS-CoV-2. T cell analysis in mice demonstrated the ability of CVnCoV to induce high S-specific CD4 + and CD8 + T cell responses. T cells are known to contribute to protection in respiratory infections, with virus-specific CD8 + T cells representing effectors of viral clearance from lung tissue (Schmidt and Varga, 2018) . In a clinical study, influenza-specific CD8 + T cells protected against symptomatic influenza infection in the absence of protective antibodies (Sridhar et al., 2013) .

Furthermore, memory CD8 + T cells provided substantial protection in a lethal SARS-CoV-1 mouse model (Channappanavar et al., 2014) . In the context of SARS-CoV-2 the protection mediated by viral specific T cells including its contribution to herd immunity (Lipsitch et al., 2020) is still under debate. Importantly, data presented here demonstrate a favourable safety profile of CVnCoV. A potential risk of vaccine development is the induction of vaccine-enhanced disease or pathology, either induced by antibodies (antibody-dependent enhanced disease, ADE) or vaccine-associated enhanced respiratory disease (VAERD) (reviewed in (Smatti et al., 2018) , (Graham, 2020) , (Lee et al., 2020; Smatti et al., 2018) . ADE, that leads to exacerbated disease by enhancement of viral entry, has been described for a feline coronavirus (Olsen et al., 1992) as well as for other viruses such as respiratory syncytial virus (RSV) and measles virus. ADE has largely been associated with the presence of non-neutralizing antibodies (reviewed in (Lee et al., 2020) ). VAERD that occurred in the context of whole-inactivated vaccines (Fulginiti et al., 1967) , (Kim et al., 1969) has been linked to inflammation induced by TH2biased immune responses and high ratios on non-neutralising to neutralising antibodies due to presentation of conformationally incorrect antigens (reviewed in (Graham, 2020) ). Vaccine-enhanced disease has been described in non-clinical models for SARS and MERS-CoV (reviewed in (Yong et al., 2019) , (Song et al., 2019) ). There is no evidence of vaccine-enhanced disease in animal models of SARS-CoV-2 (van Doremalen et al., 2020), , (Mercado et al., 2020) , (Guebre-Xabier et al., 2020) , nor clinical evidence that this might be a concern in SARS-CoV-2 infections.

However, such hypothetical effects need to be carefully excluded during vaccine development. Several lines of evidence imply that the risk of CVnCoV to induce vaccine-enhanced disease is low. Firstly, immunogenicity data generated in two animal models demonstrated robust levels of VNTs compared to binding antibodies upon vaccination with CVnCoV. Secondly, the vaccine elicited a balanced Th1/Th2 profile, indicated by the induction of equivalent levels of IgG1 and IgG2a antibodies which exhibited comparable relative avidity to SARS-CoV-2 S as well as a cytokine profile in mice that gave no indication of a TH2 bias, i.e. induction of IL4, IL5 and IL13. In addition, challenge infection in hamsters did not revealed evidence of disease enhancement, neither by enhanced viral levels in the respiratory tract, nor inflammation of lung tissue. This observation remained true in a group of animals vaccinated with 2µg, a suboptimal dose of CVnCoV that induced high levels of binding antibodies in the absence of significant virus neutralizing titres. Here, viral challenge led to breakthrough viral replication in the lungs. However, neither viral levels nor tissue inflammation was enhanced giving strong support for a favourable safety profile of CVnCoV.

We conclude that CVnCoV represents a potent and safe vaccine candidate against SARS-CoV-2. The presented data supported the start of CVnCoV clinical trials. Phase 1 and 2 evaluation of CVnCOV is currently ongoing and data are collected to initiate pivotal phase 3 clinical testing.

The mRNA vaccine is based on the RNActive ® platform (claimed and described in e.g. WO2002098443 and WO2012019780) ) and is comprised of a 5′ cap structure, a GC-enriched open reading frame (ORF), 3′ UTR, polyA tail and does not include chemically modified nucleosides. Lipid nanoparticle (LNP)encapsulation of mRNA was performed by Acuitas Therapeutics (Vancouver, Canada) or Polymun Scientific Immunbiologische Forschung GmbH (Klosterneuburg, Austria). The LNPs used in this study are particles of ionizable amino lipid, phospholipid, cholesterol and a PEGylated lipid. The mRNA encoded protein is based on the spike glycoprotein of SARS-CoV-2 NCBI Reference Sequence NC_045512.2, GenBank accession number YP_009724390.1 and encodes for full length S featuring K986P and V987P mutations.

In vitro translation was performed using Rabbit Reticulocyte Lysate System, Nuclease Treated 

Animals were injected intramuscularly (IM) with LNP-formulated SARS-CoV-2 mRNAs (CVnCoV), NaCl or 1.5 µg of recombinant SARS-CoV-2 spike protein (S1+S2 ECD, His tag; Sino Biological, Cat. 40589-V08B1) adjuvanted in Alhydrogel (Brenntag) 2% as buffer and positive control, respectively. As an additional positive control, hamsters were infected intranasally (IN) with 10 2 TCID50/dose of SARS CoV-

Animals were challenged by infection IN with 10 2 TCID50/dose of SARS CoV-2 (BetaCoV/Munich/BavPat1/2020) in a total dose volume of 0.1 ml on day 56, four weeks following the second immunisation. Animals were followed for four days post challenge (p.c.) and euthanised on day 60 of the experiment.

Blood samples were taken via retro-orbital bleeding and SARS-CoV-2 S -specific IgG1 and IgG2a antibodies (mice) or total IgG (hamster) antibodies were detected via ELISA. Plates were coated with 1µg/ml of SARS-CoV-2 spike protein (S1+S2 ECD, His tag; Sino Biological, Cat VN antibody titers of hamster serum samples were analysed upon heat inactivation of samples for 30 min at 56°C. Triplicate, serial two-fold dilutions were incubated with 10 2 TCID50/well SARS-CoV-2 virus for one hour at 37°C leading to a sample starting dilution of 1:10. The virus-serum mixtures were transferred to 96 well plates with Vero E6 cell culture monolayers and incubated for five days at 37°C.

Plates were then scored using the vitality marker WST8 and (100% endpoint) VN titers were calculated according to the method described by Reed & Muench. Analyses were was done at Viroclinics Xplore (Schaijk, The Netherlands).

The induction of antigen-specific T cells was determined using intracellular cytokine staining (ICS). For 

Blood samples were taken via retro-orbital bleeding 14h after administration of CVnCoV or buffer. Serum cytokines (IFN- IL-1, TNF, IL-6, IL-4, IL-5 and IL-13) were assessed using cytometric bead array (CBA) using the BD FACS CANTO II. Serum was diluted 1:4 and BD Bioscience mouse cytokine flex sets were used according to manufacturer's protocol to determine serum cytokine levels. IFN-α was quantified using VeriKine-HS Mouse IFN Serum ELISA Kit (pbl, Cat. 42115-1) according to manufacturer's instructions. Sera were diluted 1:100 and 50µl of the dilution was tested.

Detectable levels of replication competent virus in throat swabs, lung and nasal turbinate tissues post challenge were analysed. Quadruplicate, 10-fold serial dilutions were transferred to 96 well plates with Vero E6 cell culture monolayers and incubated for one hour at 37°C. Cell monolayers were washed prior to incubation for five days at 37°C. Plates were then scored using the vitality marker WST8 and viral titers (Log10 TCID50/ml or /g) were calculated using the method of Spearman-Karber. Analyses were done at Viroclinics Xplore (Schaijk, The Netherlands).

Histopathological analysis was performed on tissues sampled on day 4 post challenge. After fixation with 10% formalin, sections were embedded in paraffin and the tissue sections were stained with haematoxylin and eosin for histological examination. Histopathological assessment scoring is as follows:

Alveolitis severity, bronchitis/bronchiolitis severity: 0 = no inflammatory cells, 1 = few inflammatory cells, 2 = moderate number of inflammatory cells, 3 = many inflammatory cells. Alveolitis extent, 0 = 0%, 1 = <25%, 2 = 25-50%, 3 = >50%. Alveolar oedema presence, alveolar haemorrhage presence, type II pneumocyte hyperplasia presence, 0 = no, 1 = yes. Extent of peribronchial/perivascular cuffing, 0 = none, 1 = 1-2 cells thick, 2 = 3-10 cells thick, 3 = >10 cells thick. 

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines

Rapid COVID-19 vaccine development

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. bioRxiv

In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and nonhuman primates

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Animal models for COVID-19

Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

New Vaccine Technologies to Combat Outbreak Situations

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. bioRxiv

The CD8 T Cell Response to Respiratory Virus Infections

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

Cell entry mechanisms of SARS-CoV

Viral-Induced Enhanced Disease Illness

From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 11

Cellular immune correlates of protection against symptomatic pandemic influenza

A thermostable messenger RNA based vaccine against rabies

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

A pneumonia outbreak associated with a new coronavirus of probable bat origin